Inhaled and nasal delivery has specific advantages as a delivery platform outside of its traditional use for asthma/COPD and seasonal rhinitis/sinusitis however inhaled and nasal targets can offer advantages for the delivery of therapeutic biologics in the context of a shifting landscape for drug delivery. During this presentation, which was recorded for the Global Drug Delivery and Formulation Summit DDF (Berlin, 9-10th March), Intertek's Technical Director, Mark Parry, provides an overview of current technologies available and successfully marketed products with a look at the challenges, and solutions available, when formulating for these delivery routes.

Please complete the form to access the slides and the recording.